{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:40:13Z","timestamp":1792716013318,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of the current study was to evaluate the diagnostic performances of GAAD score, PIVKA-II and alpha-fetoprotein (AFP) for hepatocellular carcinoma (HCC) surveillance in HCC, chronic liver disease (CLD) and healthy controls (HC) subjects from the northeastern Peninsular Malaysia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center cross-sectional study. The GAAD value was calculated using the Elecsys\u00ae GAAD calculator. Serum PIVKA-II and AFP levels were measured using the Elecsys\u00ae electrochemiluminescence immunoassay method. Diagnostic performance of these tests were evaluated based on area under the curve (AUC), optimal cutoff levels, sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 128 enrolled subjects,99 were included (33 HCC, 33 CLD, and 33 HC). GAAD score, PIVKA-II, and AFP levels were significantly higher in patients with HCC than in those with CLD and HC (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). For differentiating HCC from CLD, GAAD at a cutoff of 2.57 demonstrated the highest Se (81.8%) and Sp (72.7%), with an AUC of 0.873 (95% CI 0.791\u20130.955). PIVKA-II at a cut-off of 28.4\u00a0ng\/mL showed Se and Sp of 75.8% and 69.7%, respectively, with an AUC of 0.842 (95% CI 0.748\u20130.936). AFP at a cutoff of 20\u00a0ng\/mL demonstrated lower Se (51.5%) but higher Sp (90.9%), with an AUC of 0.834 (95% CI 0.730\u20130.938). For differentiating HCC from HC, GAAD and PIVKA-II achieved 100% Sp and PPV, whereas AFP maintained 100% Sp but lower Se (51.52%). Overall, GAAD exhibited the best balance of sensitivity and specificity for HCC detection, while PIVKA-II provided complementary diagnostic value due to its high specificity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The GAAD score demonstrated superior diagnostic performance compared with both PIVKA-II and AFP in differentiating HCC from CLD and HC subjects, supporting its potential utility in HCC surveillance. In addition, PIVKA-II showed better diagnostic performance than AFP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-05140-6","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:04:44Z","timestamp":1784959484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic performance of GAAD, PIVKA-II and AFP in hepatocellular carcinoma, chronic liver disease and healthy population: evidence from a Malaysian cohort"],"prefix":"10.1186","volume":"26","author":[{"given":"Rabiatul Adawiyyah Mohamad","family":"Noor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Karyatee","family":"Kassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniza Mohammed","family":"Jelani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee Yeong","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Hafizuddin","family":"Husin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Muhamad Amir W","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurhanis Syazni","family":"Roslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"5140_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nat Rev Dis Primers"},{"key":"5140_CR2","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.2147\/JHC.S556306","volume":"12","author":"WL Luo","year":"2025","unstructured":"Luo WL, Wang QB, Li YK, Liang YB, Li J, Chen XM, et al. Impact of Middle Hepatic Vein Resection During Hemihepatectomy on Surgical Outcomes and Long-Term Prognosis in Hepatocellular Carcinoma: A Retrospective Study. J Hepatocell Carcinoma. 2025;12:2681\u201392. . https:\/\/doi.org\/10.2147\/JHC.S556306","journal-title":"J Hepatocell Carcinoma"},{"key":"5140_CR3","doi-asserted-by":"publisher","unstructured":"Caines A, Ford Health H, Selim R, Org R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. 2020;8(2020). https:\/\/doi.org\/10.1016\/j.cld.2020.06.001.","DOI":"10.1016\/j.cld.2020.06.001"},{"issue":"3","key":"5140_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"5140_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","volume":"72","author":"AG Singal","year":"2020","unstructured":"Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250\u201361.","journal-title":"J Hepatol"},{"issue":"1","key":"5140_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5005\/jp-journals-10018-1259","volume":"8","author":"R Mohamed","year":"2018","unstructured":"Mohamed R, Raihan R, Azzeri A, Shabaruddin FH. Hepatocellular carcinoma in Malaysia and its changing trend. Euroasian J Hepato-Gastroenterol. 2018;8(1):54\u20136. https:\/\/doi.org\/10.5005\/jp-journals-10018-1259.","journal-title":"Euroasian J Hepato-Gastroenterol"},{"key":"5140_CR7","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2147\/JHC.S544589","volume":"12","author":"QB Wang","year":"2025","unstructured":"Wang QB, Luo WL, Li YK, Li J, Yang ZS, Zhao K, et al. Tumor Compression of the Hepatic or Portal Vein Predicts the Presence of Microvascular Invasion and Satellite Nodules in Hepatocellular Carcinoma: A Retrospective Study. J Hepatocell Carcinoma. 2025;12:2055\u201367. https:\/\/doi.org\/10.2147\/JHC.S544589.","journal-title":"J Hepatocell Carcinoma"},{"key":"5140_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3544","author":"JD Yang","year":"2020","unstructured":"Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020. https:\/\/doi.org\/10.1136\/bmj.m3544.","journal-title":"BMJ"},{"issue":"2","key":"5140_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723\u201350. https:\/\/doi.org\/10.1002\/hep.29913.","journal-title":"Hepatology"},{"key":"5140_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061370","author":"F Pi\u00f1ero","year":"2020","unstructured":"Pi\u00f1ero F, Dirchwolf M, Pess\u00f4a MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9061370.","journal-title":"Cells"},{"key":"5140_CR11","doi-asserted-by":"publisher","unstructured":"Pi\u00f1ero F, Tanno M, Aballay Soteras G, Tisi Ba\u00f1a M, Dirchwolf M, Fassio E, et al. Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol. 2020:546\u2013569. https:\/\/doi.org\/10.1016\/j.aohep.2020.06.003.","DOI":"10.1016\/j.aohep.2020.06.003"},{"key":"5140_CR12","doi-asserted-by":"publisher","unstructured":"Fares S, Wehrle CJ, Hong H, Sun K, Jiao C, Zhang M, et al. Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma. 2024. https:\/\/doi.org\/10.3390\/cancers16081453.","DOI":"10.3390\/cancers16081453"},{"key":"5140_CR13","doi-asserted-by":"publisher","unstructured":"Force M, Park G, Chalikonda D, Roth C, Cohen M, Halegoua-Demarzio D, et al. Alpha-fetoprotein (AFP) and AFP-L3 is most useful in detection of recurrence of hepatocellular carcinoma in patients after tumor ablation and with low AFP level. Viruses. 2022;14(4).https:\/\/doi.org\/10.3390\/v14040775","DOI":"10.3390\/v14040775"},{"key":"5140_CR14","doi-asserted-by":"publisher","unstructured":"Ji J, Liu L, Jiang F, Wen X, Zhang Y, Li S, et al. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: a multi-center study in China. J Clin Lab Anal. 2021;35(11). https:\/\/doi.org\/10.1002\/jcla.24013.","DOI":"10.1002\/jcla.24013"},{"key":"5140_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1823","author":"N Adeniji","year":"2021","unstructured":"Adeniji N, Dhanasekaran R. Current and emerging tools for hepatocellular carcinoma surveillance. Hepatol Commun. 2021;5(12):1972\u201386.","journal-title":"Hepatol Commun"},{"key":"5140_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000537897","volume":"13","author":"M Kudo","year":"2024","unstructured":"Kudo M. Urgent global need for PIVKA-II and AFP-L3 measurements for surveillance and management of hepatocellular carcinoma. Liver Cancer. 2024;13:113\u20138. https:\/\/doi.org\/10.1159\/000537897.","journal-title":"Liver Cancer"},{"issue":"15","key":"5140_CR17","doi-asserted-by":"publisher","first-page":"1623670","DOI":"10.3389\/fonc.2025.1623670","volume":"17","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Liu Z, Wang R, Song L, Fan W, Liang P, et al. Differentiation of AFP-negative hepatocellular carcinoma from other intrahepatic malignant lesions by a noninvasive predictive model based on Sonazoid contrast-enhanced ultrasound. Front Oncol. 2025;17(15):1623670. https:\/\/doi.org\/10.3389\/fonc.2025.1623670.","journal-title":"Front Oncol"},{"issue":"2","key":"5140_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.5005\/jp-journals-10054-0107","volume":"23","author":"SA Khan","year":"2019","unstructured":"Khan SA, Sirivelu B, Saibaba K, Sridevi N, Iyyapu K. Evaluation of diagnostic utility of protein induced by vitamin K absence\u2013II (PIVKA-II) in hepatocellular carcinoma. Indian J Med Biochem. 2019;23(2):298\u2013302. https:\/\/doi.org\/10.5005\/jp-journals-10054-0107.","journal-title":"Indian J Med Biochem"},{"key":"5140_CR19","doi-asserted-by":"publisher","unstructured":"Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer. 2021;21(1).https:\/\/doi.org\/10.1186\/s12885-021-08138-3.","DOI":"10.1186\/s12885-021-08138-3"},{"key":"5140_CR20","doi-asserted-by":"publisher","unstructured":"Xu F, Zhang L, He W, Song D, Ji X, Shao J. The diagnostic value of serum PIVKA-II alone or in combination with AFP in Chinese hepatocellular carcinoma patients. Dis Markers. 2021;2021. https:\/\/doi.org\/10.1155\/2021\/8868370.","DOI":"10.1155\/2021\/8868370"},{"issue":"22","key":"5140_CR21","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJM198405313102204","volume":"310","author":"LA Horward","year":"1984","unstructured":"Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B. Des-\u03b3-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310(22):1427\u201331.","journal-title":"N Engl J Med"},{"key":"5140_CR22","unstructured":"Chan HL, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Eiblmaier A, Klein H-G, Kolja Hegel J, Kroeniger K, Madin K, Sharma A, Piratvisuth T. Performance Evaluation of the Elecsys \u00ae GAAD Assay for the Detection of Hepatocellular Carcinoma Across Different Disease Stages and Etiologies. 2021. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"5140_CR23","unstructured":"Huang CF, Sharma A, Yu ML. The clinical utility of Elecsys\u00ae GAAD score in the diagnosis of hepatocellular carcinoma. In 2022 APASL single top conference on hepatocellular carcinoma. 2022."},{"issue":"5","key":"5140_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hepr.13892","volume":"53","author":"K Hasegawa","year":"2023","unstructured":"Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, et al. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53(5):383\u201390. https:\/\/doi.org\/10.1111\/hepr.13892.","journal-title":"Hepatol Res"},{"issue":"2","key":"5140_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3350\/cmh.2022.0212","volume":"29","author":"DY Kim","year":"2023","unstructured":"Kim DY, Toan BN, Tan CK, Hasan I, Setiawan L, Yu ML, et al. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clin Mol Hepatol. 2023;29(2):277\u201392.","journal-title":"Clin Mol Hepatol"},{"key":"5140_CR26","unstructured":"G P ower 3.1.9.2 software, reference: . https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8441096\/"},{"issue":"7","key":"5140_CR27","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/MEG.0000000000002548","volume":"35","author":"R Mohamed","year":"2023","unstructured":"Mohamed R, Yip C, Singh S. Understanding the knowledge, awareness, and attitudes of the public towards liver diseases in Malaysia. Eur J Gastroenterol Hepatol. 2023;35(7):742\u201352. https:\/\/doi.org\/10.1097\/MEG.0000000000002548.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5140_CR28","doi-asserted-by":"crossref","unstructured":"Yu CJ, Yan P, Fong LC, Muhammad M, Said Abu Hass SAT. Aetiologies of Liver Cirrhosis among Adult Patients attending a Hepatology Clinic at Selangor, Malaysia. Int J Public Health Res. 2022;12(1). Retrieved from https:\/\/spaj.ukm.my\/ijphr\/index.php\/ijphr\/article\/view\/309.","DOI":"10.17576\/ijphr.1201.2022.03"},{"key":"5140_CR29","doi-asserted-by":"crossref","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma.Hepatology. 2021;73:4-13.","DOI":"10.1002\/hep.31288"},{"key":"5140_CR30","doi-asserted-by":"crossref","unstructured":"Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellularcarcinoma: epidemiology, prevention and management. J Gastrointest Oncol. 2021;12(Suppl 2):5361.","DOI":"10.21037\/jgo.2020.02.08"},{"issue":"1","key":"5140_CR31","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s12672-025-03651-4","volume":"16","author":"TTT Pham","year":"2025","unstructured":"Pham TTT, Ho DT, Nguyen TB, Phan HT. Clinical performance of GAAD score, alpha-fetoprotein, and PIVKA-II in diagnosing hepatocellular carcinoma in the Vietnamese cohort. Discov Oncol. 2025;16(1):1813. https:\/\/doi.org\/10.1007\/s12672-025-03651-4.","journal-title":"Discov Oncol"},{"key":"5140_CR32","doi-asserted-by":"publisher","unstructured":"Hadi H, Wan Shuaib WMA, Raja Ali RA, Othman H. Utility of PIVKA-II and AFP in differentiating hepatocellular carcinoma from non-malignant high-risk patients. Medicina (Kaunas). 2022;58(8). https:\/\/doi.org\/10.3390\/medicina58081015.","DOI":"10.3390\/medicina58081015"},{"key":"5140_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.726213","author":"Y Yang","year":"2021","unstructured":"Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J. Progression of prothrombin induced by vitamin K absence-II in hepatocellular carcinoma. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.726213.","journal-title":"Front Oncol"},{"key":"5140_CR34","doi-asserted-by":"crossref","unstructured":"Chan HL, Vogel A, Berg T, de Toni E, Kudo M, Trojan J, Malinowsky K, Findeisen P, Klein H-G, Kolja Hegel J, Sch\u00f6ning W, Kroeniger K, Madin K, Sharma A, Piratvisuth T. SAT597 A comparative analysis of Elecsys\u00ae GALAD and Elecsys\u00ae GAAD score to detect early-stage hepatocellular carcinoma in an international cohort. J Hepatol. 2022.","DOI":"10.1016\/S0168-8278(22)02154-7"},{"issue":"11","key":"5140_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000317","volume":"7","author":"T Piratvisuth","year":"2023","unstructured":"Piratvisuth T, Hou J, Tanwandee T, Berg T, Vogel A, Trojan J, et al. Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies. Hepatol Commun. 2023;7(11):e0317. https:\/\/doi.org\/10.1097\/HC9.0000000000000317.","journal-title":"Hepatol Commun"},{"key":"5140_CR36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1515\/labmed-2024-0208","volume":"49","author":"NT Hai","year":"2025","unstructured":"Hai NT, Doi NA, Nguyen NH, Hoang PD, Thu NK, Vu TT, et al. Diagnostic validation of the GAAD algorithm for hepatitis B virus-related hepatocellular carcinoma surveillance in Vietnam. J Lab Med. 2025;49:206\u201314.","journal-title":"J Lab Med"},{"issue":"2","key":"5140_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jimed.2021.02.004","volume":"4","author":"Q Lee","year":"2021","unstructured":"Lee Q, Yu X, Yu W. The value of PIVKA-\u2161 versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma. J Interv Med. 2021;4(2):77\u201381. https:\/\/doi.org\/10.1016\/j.jimed.2021.02.004.","journal-title":"J Interv Med"},{"key":"5140_CR38","doi-asserted-by":"publisher","unstructured":"Perne MG, Sitar-T\u0103ut A-V, Alexescu TG, Cium\u0103rnean L, Milaciu M-V, Coste S-C, Vlad C-V, Cozma A, Sitar-T\u0103ut D-A, Hilda O, Or\u0103san O, Cr\u0103ciun A. Diagnostic Performance of Extrahepatic Protein Induced by Vitamin K Absence in the Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. 2023. https:\/\/doi.org\/10.3390\/diagnostics13050816.","DOI":"10.3390\/diagnostics13050816"},{"key":"5140_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.33393\/jcb.2023.2453","volume":"12","author":"T Suttichaimongkol","year":"2023","unstructured":"Suttichaimongkol T, Mitpracha M, Tangvoraphonkchai K, Sadee P, Sawanyawisuth K, Sukeepaisarnjaroen W. PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients. J Circ Biomarkers. 2023;12:12\u20136. https:\/\/doi.org\/10.33393\/jcb.2023.2453.","journal-title":"J Circ Biomarkers"},{"issue":"1","key":"5140_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/JCLA.24823","volume":"37","author":"S Tian","year":"2023","unstructured":"Tian S, Chen Y, Zhang Y, Xu X. Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma. J Clin Lab Anal. 2023;37(1):e24823. https:\/\/doi.org\/10.1002\/JCLA.24823.","journal-title":"J Clin Lab Anal"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05140-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05140-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05140-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:21:47Z","timestamp":1792714907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05140-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5140"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05140-6","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was reviewed and approved by the Human Research Ethics Committee of University Sains Malaysia (USM\/JEPeM\/18010058) and in line with the Helsinki Declaration. All subjects signed the informed consent form for the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The manuscript does not contain any individual person\u2019s data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"690"}}